Journal of Clinical Endocrinology & Metabolism, Vol 67, 1-5, Copyright © 1988 by Endocrine Society

ARTICLES

Effects of omega-3 fish oils on lipid metabolism, glycemic control, and blood pressure in type II diabetic patients

SE Kasim, B Stern, S Khilnani, P McLin, S Baciorowski and KL Jen
Department of Medicine, Wayen State University, Detroit, Michigan 48202.

We investigated the effects of omega-3 fish oil (FO) supplementation on lipid metabolism, glycemic control, and blood pressure (BP) in patients with type II diabetes mellitus. In 22 diabetic patients without overt hyperlipidemia, serum triglyceride, total cholesterol, high density lipoprotein (HDL)-cholesterol, HDL2-cholesterol, HDL3-cholesterol, and apolipoprotein A-I (apo A-I) levels did not change during omega-3 FO supplementation for 8 weeks. The mean serum apo B concentration increased significantly [baseline, 2.56 +/- 0.11 (+/- SEM) mmol/L; 4 weeks, 2.82 +/- 0.13 mmol/L; 8 weeks, 2.80 +/- 0.13 mmol/L; P less than 0.01]. The mean plasma postheparin lipoprotein lipase activity increased transiently during the fourth week (baseline, 168 +/- 17 U/mL; 4 weeks, 182 +/- 18 U/mL; P less than 0.05), whereas postheparin hepatic triglyceride lipase activity did not change. Glycemic control worsened transiently during the fourth week, (baseline, 7.7 +/- 0.4%; 4 weeks, 8.4 +/- 0.3%; P less than 0.05). Both systolic and diastolic BP decreased significantly throughout the study (systolic BP: baseline, 142 +/- 5 mm Hg; 8 weeks, 128 +/- 5 mm Hg; diastolic BP: baseline, 88 +/- 4 mm Hg; 8 weeks, 80 +/- 3 mm Hg; P less than 0.01). These findings suggest that in type II diabetics without overt hyperlipidemia, omega-3 FO supplementation does not improve either the glycemic control or serum lipids, and it is associated with a potentially detrimental rise in serum apo B concentrations. Until more information is available, use of such supplementation should be discouraged.

This article has been cited by other articles:

				R. De Caterina, R. Madonna, A. Bertolotto, and E. B. Schmidt n-3 Fatty Acids in the Treatment of Diabetic Patients: Biological rationale and clinical data Diabetes Care, April 1, 2007; 30(4): 1012 - 1026. [Full Text] [PDF]

				S. E. Kasim-Karakas, R. U. Almario, L. Gregory, R. Wong, H. Todd, and B. L. Lasley Metabolic and Endocrine Effects of a Polyunsaturated Fatty Acid-Rich Diet in Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 615 - 620. [Abstract] [Full Text] [PDF]

				R. J Woodman, T. A Mori, V. Burke, I. B Puddey, G. F Watts, and L. J Beilin Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension Am. J. Clinical Nutrition, November 1, 2002; 76(5): 1007 - 1015. [Abstract] [Full Text] [PDF]

				R. U Almario, V. Vonghavaravat, R. Wong, and S. E Kasim-Karakas Effects of walnut consumption on plasma fatty acids and lipoproteins in combined hyperlipidemia Am. J. Clinical Nutrition, July 1, 2001; 74(1): 72 - 79. [Abstract] [Full Text] [PDF]

				D. J. Jenkins, C. W. Kendall, E. Vidgen, S. Agarwal, A V. Rao, R. S Rosenberg, E. P Diamandis, R. Novokmet, C. C Mehling, T. Perera, et al. Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: a controlled crossover trial Am. J. Clinical Nutrition, March 1, 1999; 69(3): 395 - 402. [Abstract] [Full Text] [PDF]

				I. Toft, K. H. Bonaa, O. C. Ingebretsen, A. Nordoy, and T. Jenssen Effects of n-3 Polyunsaturated Fatty Acids on Glucose Homeostasis and Blood Pressure in Essential Hypertension: A Randomized, Controlled Trial Ann Intern Med, December 15, 1995; 123(12): 911 - 918. [Abstract] [Full Text]